Physician profile
Scott E Moseman
NPI 1568432607
$955.78
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $109 · 2022: $148 · 2023: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $260.65 | 2019-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $114.02 | 2019-2023 | Spravato |
| Lundbeck LLC | $107.97 | 2020-2023 | Rexulti |
| Corium, LLC | $105.78 | 2022-2023 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $83.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.19 | 2019-2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $43.12 | 2022-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $31.55 | 2023 | Quviviq |
| Alkermes, INC. | $29.34 | 2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.63 | 2022 | |
| Axsome Therapeutics, INC. | $24.72 | 2023 | Auvelity |
| Shire North American Group INC | $24.27 | 2019 | |
| Neos Therapeutics, LP | $18.38 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.55 | 2019 | |
| Vanda Pharmaceuticals INC. | $12.18 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Moseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.